Метформин – от терапии метаболического синдрома к профилактике сахарного диабета типа 2 и сердечно-сосудистых заболеваний
- Авторы: Бирюкова Е.В1
-
Учреждения:
- ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава РФ
- Выпуск: Том 15, № 10 (2013)
- Страницы: 144-149
- Раздел: Статьи
- URL: https://bakhtiniada.ru/2075-1753/article/view/93981
- ID: 93981
Цитировать
Полный текст
Аннотация
Лечение метаболического синдрома (МС) метформином в сочетании с нефармакологическими методами не только улучшает тканевую чувствительность к инсулину и метаболизм глюкозы, но и положительно влияет на многочисленные факторы риска сердечно-сосудистых заболеваний, замедляя развитие и прогрессирование атеросклеротического процесса. Учитывая широкий спектр фармакологических эффектов, метформин должен найти широкое применение в комплексной терапии МС.
Ключевые слова
Полный текст
Открыть статью на сайте журналаОб авторах
Е. В Бирюкова
ГБОУ ВПО МГМСУ им. А.И.Евдокимова Минздрава РФКафедра эндокринологии и диабетологии
Список литературы
- Abbasi F, Chu J.W, Mc Laughlin T et al. Effect of metformin treatment on multiple cardiovascular disease risk factors in patients with type 2 diabetes mellitus. Metabolism 2004; 53 (2): 159–64.
- Ajjan R.A, Grant P.J. Cardiovascular disease prevention in patients with type 2 diabetes: The role of oral anti - diabetic agents. Diab Vasc Dis Res 2006; 3 (3): 147–58.
- Bailey C.J, Turner R.C. Metformin. N Engl J Med 1996; 334: 574–9.
- Cicero A.F, Tartagni E, Ertek S. Metformin and its clinical use: new insights for an old drug in clinical practice. Arch Med Sci 2012; 8 (5): 907–17.
- Coutinho M, Gerstein H, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events, a metaregression analysis of published data from 20 studies of 95 783 individuals followed for 12,4 years. Diabetes Care 1999; 22: 233–40.
- Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifesyill intervention or metformin. N Engl J Med 2002; с. 346, 393–403.
- Dunstan D.W, Zimmet P.Z, Welborn T.A et al. The rising prevalence of diabetes mellitus and impaired glucose tolerance: The Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2002; 25: 829–34.
- Ford E.S. The metabolic syndrome and mortality from cardiovascular disease and all - causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173: 309–14.
- Gagnon J, Sheppard E, Anin Y.I. Metformin directly inhibits ghrelin secretion through AMP-activated protein kinase in rat primary gastric cells. Diab Obes and Metab 2013;15 (3): 276–9.
- Grand P.J. Beneficial effects of metformin on hemostasis and vascular function in man. Diabetes Metаb 2003; 29: 6S45–6S52.
- Haffner S.M, Lehto S, Ronnemaa T et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998; 339: 229–34.
- He L, Sabet A, Djedjos S et al. Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell 2009; 15; 137 (4): 635–46.
- International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome; http://www.idf.org/webdata/docs/ IDF_Metasyndrome_definition.pdf Accessed October 4, 2005.
- Isoda K, Young J.L, Zirlik A et al. Metformin inhibits proinflammatory responses and nuclear Factor - kappa B in human vascular wall cells. Arterioscler Thromb Vasc Biol 2006; 26 (3): 611–7.
- Kolluru G.K, Bir S.C, Kevil C.G. Endothelial dysfunction and diabetes: effects on angiogenesis, vascular remodeling, and wound healing. Int J Vasc Med 2012; doi: 10.1155/2012/918267.
- Malesker M.A. Optimizing antidiabetic treatment options for patients with type 2 diabetes mellitus and cardiovascular comorbidities. Pharmacotherapy 2008; 28 (2): 193–206.
- Mazzone T, Chait A, Plutsky J. Cardiovascular disease risk in type 2 diabetes mellitus: Insights from mechanistic studies. Lancet 2008; 371: 1800–9.
- Meier M, Hummel M. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence - based strategies. Vasc Health Risk Manag 2009; 5: 859–71.
- Bailey C.J, Campbell I.W, Chan J.C.N et al. Metformin. The gold standard. A scientific handbook (Text). England: John Wiley & Sons, Ltd, 2007.
- Miranda P.J, De Fronzo R.A, Califf R.M, Guyton J.R. Metabolic syndrome: definition, pathophysiology, and mechanisms. Am Heart J 2005; 149 (1): 33–45.
- Ouslimani N, Mahrouf M, Peynet J et al. Metformin reduces endothelial cell expression of both the receptor for advanced glycation end products and lectin - like oxidized receptor 1. Metabolism 2007; 56 (3): 308–13.
- Park J.H, Kwon H.M, Roh J.K. Metabolic syndrome is more associated with intracranial atherosclerosis than extracranial atherosclerosis. Eur J Neurol 2007; 14 (4): 379–86.
- Salpeter S.R, Buckley N.S, Kahn J.A, Salpeter E.E. Meta - analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008; 121: 149–57.
- Scarpello J.H.B, Howlett H.C.S. Metformin therapy and clinical uses. Vasc Dis Res 2008; 5: 157–67.
- Standards of Medical Care in Diabetes 2011. Diabetes Care 2011; 34 (Suppl. 1): 11–61.
- Standards of Medical Care in Diabetes 2012. Diabetes Care 2012; 35 (Suppl. 1): 11–63.
- Viollet B, Guigas B, Garcia N.S. Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) 2012; 122 (6): 253–70.
- UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–8.
- Uygun A et al. Metformin in the treatment of patients with non - alcoholic steatogepatitis. Phormacol Ther 2004; 19: 537–44.
- Viner R.M, Segal T.Y, Lichtarowicz-Krynska E, Hindmarsh P. Prevalence of the insulin resistance syndrome in obesity. Arch Dis Child 2005; 90: 10–4.
- Zimmet P.Z, Alberti K.G. Introduction: Globalization and the non - communicable disease epidemic. Obesity (Silver Spring) 2006; 14: 1–3.
Дополнительные файлы
